Aktienanalyse zu Veru Inc (VERU)VERUVeru Inc

Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Veru Inc. appears to be a good buy right now due to its current price of $2.16, which is significantly lower than its 52-week high of $7.33, indicating potential for recovery. The RSI is at 31.08, suggesting the stock is oversold, which could lead to a price rebound. Additionally, the company has a strong cash position of $23.9 million, which supports ongoing R&D efforts. The main risk is the forward P/E ratio of 117.65, indicating that the stock may be overvalued based on future earnings expectations, but the potential upside from clinical trials could outweigh this risk.

1 analysts cover VERU: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 25.00.